help_outline Skip to main content
Add Me To Your Mailing List
Organization of Regulatory and Clinical Associates
Contact Information:
Organization of Regulatory and Clinical Associates
P.O. Box 3490
Redmond, WA 98073
HomeCurrent/Future EventsWebinar - Boundary Conditions in Early Clinical Trials

Current/Future Events - Event View

This is the "Event Detail" view, showing all available information for this event. If the event has passed, click the "Event Report" button to read a report and view photos that were uploaded.

Webinar - Boundary Conditions in Early Clinical Trials

When:
Wednesday, April 15, 2020, 8:00 AM until 10:00 AM
Additional Info:
Event Contact(s):
ORCA Admin
Category:
Webinar
Registration is closed
Payment In Full In Advance Only
RSVP by Tuesday, April 14 2020

Meetings and webinars are scheduled on Pacific Standard Time or Pacific Daylight Time, whichever applies.

Please make sure that the following email address is in your Safe Sender list: mailer@mail2.clubexpress.com. System messages like meeting announcements, registration confirmations, webinar login instructions as well as certificates of attendance are sent directly from this email address.

You will receive an email 2 days prior to the meeting date with the webinar login instructions or after payment is processed if registering closer to the meeting date. If you don't receive the instructions within this time frame, please contact us at info@orcanw.org as soon as possible.

PAID FEES ARE NON REFUNDABLE.

For webinar events, payment is REQUIRED at the time of registration.
Capacity:
100
No Fee
$60.00

The link to the webinar is intended for the registered person ONLY and should not be shared.
All attendees MUST be registered.
This webinar will be recorded.

NEW START TIME is 8:00 AM PST

TOPIC: The influence of boundary conditions on clinical data and the importance of standardization in early clinical drug development

TOPIC DESCRIPTION: Clinical trials in early clinical drug development, also known as phase I (tolerability and ADME (absorption, distribution, metabolism and excretion) and phase IIa (proof of concept) are characterized by low sample size. It is therefore of great importance to keep the inter- and intra-individual variability of clinical data as low as possible. On the other hand, important decisions have to be made on go or no-go to full clinical drug development on the basis of limited data resulting from first clinical trials. Focusing on boundary conditions and their standardization is therefore mandatory for a successful early clinic drug development.

SPEAKER: Dr. Karl M. Eckl

SPEAKER BIOGRAPHY: Karl M. Eckl was trained in physics and medicine with special training in biophysics. For 34 years he is now involved in clinical research. During the first seven years Dr. Karl M. Eckl learned the basics in drug development in pharmaceutical companies like Beacham-Wülfing, Beach Pharmaceuticals and SmithKline Beecham.

Since 1992, he is entrepreneur and specialized in early clinical drug development. As investigator in more than 300 clinical trials Dr. Karl M. Eckl gained experience on the practical approach performing clinical trials in the early phase of clinical drug development.


WHO: Clinical, regulatory, quality, manufacturing and legal

Attendance at this meeting may be applied as 1.5 points towards RAC re-certification